Applying Biomarker Information To Support Drug Discovery ... - IIR

More documents

Recommendations

Info

Immunogenicity of PEG-IFN and IFN in Mice Antibody Titer a Treatment Median Range IFN (monomeric) 120 11 - 427 IFN (aggregates) 2133 400 - 38,400 PEG-IFN 0 0 - 57 a using cell proliferation assay with 20-fold dilution
Comparison of Pharmacokinetic Profiles between PEG-IFN and IFN 1000 Serum Conc. (U/ml) 100 10 IFN 3 MIU PEG-IFN 270 μg 1 0 50 100 150 200 Time (hr)
Page 1 and 2: Applying Biomarker Information To S
Page 3 and 4: Definition: Surrogate Endpoint A bi
Page 5 and 6: Develop a New Therapy • Strong Me
Page 7: PK Profiles of IFN / PEG-IFN in Rat
Page 11 and 12: Good Correlation between Predicted
Page 13 and 14: Good Correlation between Model Pred
Page 15 and 16: Good Correlation between Model Pred
Page 17 and 18: Findings of PKA Signaling Pathway P
Page 19 and 20: Mechanistic Pharmacology Platform i
Page 21 and 22: Graphic Illustration -- Mechanism o
Page 23 and 24: Model Prediction vs Literature Valu
Page 25 and 26: Effect of PEG-G & Filgrastim on ANC
Page 27 and 28: Mean BFU-E Colony Formation Profile
Page 29: Acknowledgment PEGSYS Project: PKA

Applying Biomarker Information To Support Drug Discovery ... - IIR

Create successful ePaper yourself

Delete template?

Save as template?